BR112023023833A2 - Composições e métodos para tratamento de câncer de pulmão - Google Patents

Composições e métodos para tratamento de câncer de pulmão

Info

Publication number
BR112023023833A2
BR112023023833A2 BR112023023833A BR112023023833A BR112023023833A2 BR 112023023833 A2 BR112023023833 A2 BR 112023023833A2 BR 112023023833 A BR112023023833 A BR 112023023833A BR 112023023833 A BR112023023833 A BR 112023023833A BR 112023023833 A2 BR112023023833 A2 BR 112023023833A2
Authority
BR
Brazil
Prior art keywords
methods
lung cancer
compositions
treatment
treating
Prior art date
Application number
BR112023023833A
Other languages
English (en)
Portuguese (pt)
Inventor
Jarkowski Anthony Iii
Leo Trani
Michael Newton
Norah Shire
Phillip Dennis
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of BR112023023833A2 publication Critical patent/BR112023023833A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112023023833A 2021-05-24 2022-05-24 Composições e métodos para tratamento de câncer de pulmão BR112023023833A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163192217P 2021-05-24 2021-05-24
PCT/EP2022/064061 WO2022248478A1 (en) 2021-05-24 2022-05-24 Compositions and methods for treating lung cancer

Publications (1)

Publication Number Publication Date
BR112023023833A2 true BR112023023833A2 (pt) 2024-01-30

Family

ID=82100132

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023023833A BR112023023833A2 (pt) 2021-05-24 2022-05-24 Composições e métodos para tratamento de câncer de pulmão

Country Status (11)

Country Link
US (1) US20240254235A1 (https=)
EP (1) EP4347038A1 (https=)
JP (1) JP2024521105A (https=)
KR (1) KR20240012413A (https=)
CN (1) CN117425493A (https=)
AU (1) AU2022281992A1 (https=)
BR (1) BR112023023833A2 (https=)
CA (1) CA3219960A1 (https=)
IL (1) IL308530A (https=)
TW (1) TW202313107A (https=)
WO (1) WO2022248478A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120936347A (zh) * 2023-04-14 2025-11-11 阿斯利康(瑞典)有限公司 非小细胞肺癌的治疗

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ628923A (en) 2009-11-24 2016-02-26 Medimmune Ltd Targeted binding agents against b7-h1
US20190276543A1 (en) * 2018-03-08 2019-09-12 Astrazeneca Pharmaceuticals Lp Compositions and methods for treating late stage lung cancer
BR112022022304A2 (pt) * 2020-05-04 2022-12-20 Merck Sharp & Dohme Llc Métodos para tratar câncer usando uma combinação de um antagonista pd-1, uma quimiorradioterapia e um inibidor de parp

Also Published As

Publication number Publication date
IL308530A (en) 2024-01-01
JP2024521105A (ja) 2024-05-28
AU2022281992A1 (en) 2024-01-04
EP4347038A1 (en) 2024-04-10
WO2022248478A1 (en) 2022-12-01
KR20240012413A (ko) 2024-01-29
US20240254235A1 (en) 2024-08-01
CA3219960A1 (en) 2022-12-01
TW202313107A (zh) 2023-04-01
CN117425493A (zh) 2024-01-19

Similar Documents

Publication Publication Date Title
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
CL2019001353A1 (es) Compuestos con actividad antitumoral contra células cancerígenas que portan mutaciones en el exón 20 de egfr o her2.
BR112023000687A2 (pt) Métodos e combinações de inibidores de kat6 para o tratamento de câncer
MX2020009773A (es) Terapia de combinacion.
BR112021021713A2 (pt) Método de tratamento de câncer ou inibição do crescimento de um tumor
EA201792191A1 (ru) Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли
BR112019022280A2 (pt) tratamento de cânceres de her2 positivo
CR20120528A (es) Métodos para tratar el cáncer
BR112021008549A2 (pt) Método de tratamento de carcinoma pulmonar de células não pequenas com uma população de linfócitos infiltrantes de tumor
MX2021009079A (es) Metodos para tratar el mieloma multiple.
BR112022008295A2 (pt) Inibição combinada de pd-1, tgfbeta e tigit para o tratamento de câncer
MX2019013862A (es) Terapia de combinacion.
CL2022001794A1 (es) Terapia combinada que comprende inhibidores de a2a/a2b y pd-1/pd-l1.
BR112021020601A2 (pt) Compostos contra câncer contendo mutações do egfr resistentes ao inibidor da tirosina quinase
BR112022010072A2 (pt) Métodos que empregam óxido nítrico gasoso para inibir crescimento de tumor
JOP20230125A1 (ar) كانابيديول لعلاج النوبات المستعصية على العلاج
BR112023005160A2 (pt) Terapia de combinação para o tratamento de câncer
MX2024006765A (es) Terapia de combinación con adc ceacam5 - anti-pd1/pd-l1.
BR112022001045A2 (pt) Método para tratar um indivíduo com ou em risco de desenvolver um câncer associado a liv1, e, kit
CO2023017973A2 (es) Trampas de ligando del factor de crecimiento transformante βeta para el tratamiento de enfermedades
BR112023023833A2 (pt) Composições e métodos para tratamento de câncer de pulmão
BR112023022530A2 (pt) Inibidores de pcna e inibidores de egfr para tratamento de câncer
AR131101A1 (es) Heteroarilfluoroalquenos como inhibidores de dgk
CL2023003090A1 (es) Combinaciones de composiciones terapéuticas y usos para tratar cánceres
BR112022007787A2 (pt) Inibição combinada de pd-1, tgfss e atm juntamente com radioterapia para o tratamento de câncer

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]